US Senate clears PEPFAR bill with HIV treatment thresholds
This article was originally published in Scrip
Executive Summary
The US House is expected this week to approve a Senate bill renewing and expanding the President's Emergency Plan for AIDS Relief (PEPFAR) programme. The measure would require more than half of all HIV/AIDS funding be spent on treatment and open an avenue for the PEPFAR programme to purchase antiretrovirals approved by regulators other than the FDA.
You may also be interested in...
Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos
Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.
Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos
Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.